Tasly Pharmaceutical Group Co (SHSE:600535) LT-Debt-to-Total-Asset: 0.02 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600535 Tasly Pharmaceutical Group Co Ltd SHSE:600535
81 GF Score
Price ¥14.59
GF Value ¥15.06
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Tasly Pharmaceutical Group Co LT-Debt-to-Total-Asset?

Tasly Pharmaceutical Group Co SHSE:600535 +1.46% 81 LT-Debt-to-Total-Asset is 0.02 as of Mar. 2026. GuruFocus rates SHSE:600535 with a GF Score™ of 81/100 and a GF Value™ of ¥15.06 (Fairly Valued). The stock has 1 warning sign investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Tasly Pharmaceutical Group Co's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.02.

Tasly Pharmaceutical Group Co's long-term debt to total assets ratio increased from Mar. 2025 (0.01) to Mar. 2026 (0.02). It may suggest that Tasly Pharmaceutical Group Co is progressively becoming more dependent on debt to grow their business.

Tasly Pharmaceutical Group Co  (SHSE:600535) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Tasly Pharmaceutical Group Co LT-Debt-to-Total-Asset Related Terms

Tasly Pharmaceutical Group Co LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Tasly Pharmaceutical Group Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tasly Pharmaceutical Group Co LT-Debt-to-Total-Asset Chart

Tasly Pharmaceutical Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.07 0.09 0.09 0.02 0.02

Tasly Pharmaceutical Group Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.02 0.02 0.02
SHSE:600535
81GF Score
Tasly Pharmaceutical Group Co Ltd SHSE:600535
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tasly Pharmaceutical Group Co LT-Debt-to-Total-Asset Calculation

Tasly Pharmaceutical Group Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=268.06/15339.72
=0.02

Tasly Pharmaceutical Group Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=241.989/15693.754
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.02 mean?
Tasly Pharmaceutical Group Co (SHSE:600535) has a LT-Debt-to-Total-Asset of 0.02 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Tasly Pharmaceutical Group Co and its competitors.
Is Tasly Pharmaceutical Group Co's LT-Debt-to-Total-Asset too high?
Tasly Pharmaceutical Group Co's current LT-Debt-to-Total-Asset is 0.02. Overall, Tasly Pharmaceutical Group Co has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Tasly Pharmaceutical Group Co's LT-Debt-to-Total-Asset compare to ZTS and UTHR?
Tasly Pharmaceutical Group Co's LT-Debt-to-Total-Asset of 0.02 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?
A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Tasly Pharmaceutical Group Co and its competitors. Tasly Pharmaceutical Group Co's current LT-Debt-to-Total-Asset is 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tasly Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Tasly Pharmaceutical Group Co (SHSE:600535) is currently considered Fairly Valued. The stock's GF Value™ is ¥15.06, compared to a current price of ¥14.59 — trading 3.1% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.02. Tasly Pharmaceutical Group Co's overall GF Score™ is 81/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Tasly Pharmaceutical Group Co (SHSE:600535), the current LT-Debt-to-Total-Asset is 0.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tasly Pharmaceutical Group Co (SHSE:600535) Overvalued in 2026?

Based on GuruFocus' analysis, Tasly Pharmaceutical Group Co stock appears to be undervalued. The current stock price of ¥14.59 is trading 3.1% below its estimated GF Value™ of ¥15.06. GuruFocus considers Tasly Pharmaceutical Group Co to be Fairly Valued.

Key valuation signals for SHSE:600535:

  • LT-Debt-to-Total-Asset: 0.02
  • GF Value™: ¥15.06 vs. price of ¥14.59 (3.1% below fair value)
  • GF Score™: 81/100 with 1 warning sign

No single metric tells the full story. See the SHSE:600535 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Tasly Pharmaceutical Group Co Business Description

Address 2 Pujihe Road East, Beichen District, Tasly TCM Garden, Tianjin, CHN, 300410
Tasly Pharmaceutical Group Co Ltd is a China-based company engaged in the manufacturing and distribution of pharmaceutical products. Its herbal medicines include Tasly Cerebral Care Granules and Tasly ICP. Its chemical medicines comprise of Ketotifen Fumarate Tablets, Thiamphenicol Capsules, Glucurolactone Tablets and Sulpiride Tablets. Some of the other products offered by the company include PharmceuticalSubstances & API, HerbalExtract, and Concentrated Herbal Granules.
81GF Score

Get the complete analysis for SHSE:600535

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥14.59
Price
¥15.06
GF Value